LEILA SAHNI to Respiratory Syncytial Virus, Human
This is a "connection" page, showing publications LEILA SAHNI has written about Respiratory Syncytial Virus, Human.
Connection Strength
0.558
-
Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024 Mar 07; 73(9):209-214.
Score: 0.176
-
Respiratory viral detection in the plasma and cerebrospinal fluid (CSF) of young febrile infants. Influenza Other Respir Viruses. 2024 02; 18(2):e13250.
Score: 0.175
-
Respiratory Virus Surveillance Among Children with Acute Respiratory Illnesses - New Vaccine Surveillance Network, United States, 2016-2021. MMWR Morb Mortal Wkly Rep. 2022 Oct 07; 71(40):1253-1259.
Score: 0.160
-
Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024. JAMA Pediatr. 2025 Feb 01; 179(2):179-187.
Score: 0.047